iSpecimen Launches New Open Feasibilities Dashboard on the iSpecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network
October 27 2022 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an
online global marketplace that connects scientists in need of
biospecimens for medical research with a network of healthcare
specimen providers, today announced that the Company has launched
its new self-service Open Feasibilities Dashboard on iSpecimen
Marketplace®, allowing supplier partners to review potential future
research projects at any time and initiate their interest by
submitting a proposal. Dedicated to providing its global partner
network with increased transparency and iSpecimen Marketplace®
support, iSpecimen continues to expand access to valuable specimens
crucial for advancing medical research.
The Open Feasibilities Dashboard enables precision specimen
matchmaking to flow seamlessly through the iSpecimen Marketplace®
from providers directly to researchers, enabling partners to engage
more productively and beneficially with new and existing research
projects and requests. Suppliers can also see which specimen
projects have been flagged as being high priority and, therefore,
needing immediate feasibility assessment, obtaining additional,
ongoing opportunities to participate in revenue-generating projects
that are underway.
“iSpecimen’s Open Feasibilities Dashboard is the latest feature
in a series of recent iSpecimen Marketplace® updates focused on
addressing the current limitations in the biospecimen procurement
process. We continue to remain focused on enhancing the iSpecimen
Marketplace® platform and improving the biospecimen process to
advance scientific discovery,” said Tracy Curley, Interim CEO and
CFO, iSpecimen. “Through providing additional tools for our global
providers, we are able to fulfill diverse specimen requests at a
quicker pace and more efficiently for researchers.”
“The iSpecimen Marketplace® consistently provides us with new
and effective opportunities to help advance medical research, and
the new Open Feasibilities Dashboard gives us the ability to easily
‘shop’ for new studies on the platform in need of specimens,” added
Jesse Lansdell, LVN, Clinical Research Coordinator, CHRISTUS St.
Michael Health System, an iSpecimen provider. “Given the many
obstacles that researchers face when searching for specimens for
their work, iSpecimen continues to innovate its iSpecimen
Marketplace® to help propel lifesaving medical research
forward.”
The iSpecimen Marketplace® is a novel technology platform that
connects life sciences researchers who need
biospecimens for their research with patients and healthcare
organizations that can provide these samples. The Marketplace
specifically addresses procurement inefficiencies that have
traditionally forced researchers to limit the scope of their work
due to the shortage of quality biospecimens. Researchers can search
for biospecimens based on demographic traits, medical conditions,
procedures, blood type, country of collection and much more.
About iSpecimeniSpecimen (Nasdaq: ISPC) offers
an online marketplace for human biospecimens, connecting scientists
in commercial and non-profit organizations with healthcare
providers that have access to patients and specimens needed for
medical discovery. Proprietary, cloud-based technology enables
scientists to intuitively search for specimens and patients across
a federated partner network of hospitals, labs, biobanks, blood
centers and other healthcare organizations. For more information,
please visit www.ispecimen.com.
Forward Looking StatementsThis press release
may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as “may,” “will,” “expect,” “intend,”
“anticipate,” “believe,” “estimate” and “continue” or similar
words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company’s filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company’s forward-looking statements occurs, the Company’s
business, financial condition and operating results may vary
materially from those expressed in the Company’s forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana MarinoiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Aug 2024 to Sep 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Sep 2023 to Sep 2024